Archives
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2018-07
-
Lorlatinib is an orally active brain penetrant
2024-09-11

Lorlatinib is an orally active brain penetrant cyclic 2-aminopyridine derivative that is a type I½ B ALK inhibitor (Fig. 5F) [61]. This medicinal is an effective antagonist against the more common L1196M and G1269A crizotinib-resistant mutations as well as the less common T1151Ins, L1152R, C1156Y, F
-
br Conflict of interest br Financial Support
2024-09-11

Conflict of interest Financial Support The work is supported by research grants from Clinical Key Specialty Project of China and Clinical Medical Center of Suzhou, China (Szzx201502) and Jiangsu Province Special Program of Medical Science, China (BE2016672). Introduction Recently, function
-
br Occurrence of Inosine in RNA Inosine is
2024-09-11

Occurrence of Inosine in RNA Inosine is widespread among various types of RNAs including transfer RNA (tRNA), ribosomal RNA (rRNA), messenger RNA (mRNA), long noncoding RNA (lncRNA), and microRNA (miRNA). Within these RNAs, inosine can appear in different locations as well. Table 1 lists examples
-
br Experimental section br Conflicts of interest br Acknowle
2024-09-11

Experimental section Conflicts of interest Acknowledgments This work was partly supported by INSA-Rouen, Rouen University, CNRS, Labex SynOrg (ANR-11-LABX-0029), Région Haute-Normandie. Introduction A key component of the integrated management of key pests such as codling moth (Cydia po
-
Finally we show that the optimal corporate
2024-09-11

Finally, we show that the optimal corporate tax rate is strictly positive, balancing the increase in tax revenues against the loss in consumer surplus due to higher prices and fewer firms (products). This result is related to the well-known “excessive entry theorem” that shows, for a large class of
-
The authors thank Dr J Aoki University of Tokyo for
2024-09-10

The authors thank Dr. J. Aoki, University of Tokyo, for kindly providing 5E5-ATX antibody. This work was supported by a grant from the Deutsche Forschungsgemeinschaft to A.E.K. (KR4391/1-1), research grants “Primary sclerosing cholangitis” from the Deutsche Crohn-Colitis-Vereinigung and the Norwegia
-
br Materials and methods br Results br Discussions Our
2024-09-10

Materials and methods Results Discussions Our results indicated that autophagy was suppressed in GECs under HAGG treatment, through Akt/mTOR-dependent pathways. Previous reports provided clues for the linkages between ICs and endothelial cell autophagy. Fujii and colleagues reported that se
-
Comparison of the GLUT positive plus ACLY
2024-09-10

Comparison of the GLUT1-positive plus ACLY negative group with the GLUT1-negative plus ACLY positive group indicated no significant difference with respect to disease-free survival and overall survival. However, some obvious differences in histological types were found in their formation. A previous
-
Treatment of all of the GYN
2024-09-10

Treatment of all of the GYN cancer JNJ-10198409 in this study with ATRi not only reduced phosphorylation of Chk1 at Ser345 following genotoxic stress, but also phosphorylation of ATM. Loss of phospho-ATM following ATRi treatment is not likely due to non-specific targeting of ATM by ETP-46464 [28]. W
-
TLRs play a key role in pathogen recognition
2024-09-10

TLRs play a key role in pathogen recognition and early response. In our study, we showed an increase of TLR2 mRNA and protein expression after BMECs were stimulated by S. aureus, as seen for BMECs in a previous study [25]. Although most studies describe TLR4 as a primary receptor for Gram-negative b
-
br Conclusion br Conflicts of interest
2024-09-10

Conclusion Conflicts of interest Acknowledgements The authors are grateful to the Ministry of Food Processing Industries, Govt of India (V45/MFPI/R&D/2000 Vol.IV) and Department of Biotechnology, New Delhi, Govt. of India (BT/475/NE/TBP/20132), American Bamboo Society and Ned Jaquith Founda
-
Regardless of the initial treatment most patients with advan
2024-09-10

Regardless of the initial treatment, most patients with advanced NSCLC experience relapse and disease progression [15]. A subpopulation of immediate concern and clinical need is patients who have advanced NSCLC that is especially aggressive, which is usually defined as disease that rapidly progresse
-
Recently two distinct small molecule inhibitors
2024-09-10

Recently, two distinct small-molecule inhibitors of PHGDH were identified using high-throughput screens, both of which inhibit de novo serine biosynthesis and show selective toxicity to cancer Sodium Danshensu with high SSP flux [50,51]. The inhibitor NCT-503, which has an IC50 of 2.5μM, reduces th
-
In the MT SGL two regularization parameters need
2024-09-10

In the MT-SGL, two regularization parameters need to be specified: λ1 and λ2. Using recent results on norm regularization (Banerjee et al., 2014), it is possible to express both parameters via a single parameter as follows: and (Meier et al., 2008, Banerjee et al., 2014), where and are computed
-
br Materials and methods br Results br Discussion
2024-09-10

Materials and methods Results Discussion Competing financial interests Acknowledgements The work was partially supported by grants from the National Natural Science Foundation of China (Grant no. 31530053 and 31401424) and National Science and Technology Support Plan (Grant no. 2013BA
15215 records 102/1015 page Previous Next First page 上5页 101102103104105 下5页 Last page